Brief Title
An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster
Official Title
An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-leaving Booster to 14-15-year-old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5½ Years of Age
Brief Summary
Open-label, randomized, multi-centre study in which 400 subjects, divided into two groups,
will receive Td5ap or Td1aP as a single injection. We will then describe the immune response
and safety profile of the combined vaccine booster.
Detailed Description
The vaccines in the study are COVAXIS (Td5ap), Sanofi Pasteur Canada, and diTekiBooster
(Td1aP), Statens Serum Institut, Denmark.
The primary objective of the study is to describe the immune response to diphtheria toxin,
tetanus toxoid, pertussis toxin, filamentous haemagglutinin (FHA), fimbriae 2/3 and pertactin
four weeks after immunization with Td1aP and Td5ap.
The secondary objectives include:
- describing the safety of a fith dose of DTP vaccines in 14-15 year-old children by
observing systemic and local adverse reactions
- describing pre-booster antibody levels
- describing pre-booster and post-booster IgG and IgA levels in saliva
- describing in a subpopulation the pre-booster and post-booster T cell immune responses
as determined by the production of cytokines
- describing in a subpopulation the pre-booster and post-booster B cell immune responses
as determined by the number of effector and memory B-cells
The sample size is 400 subjects (200 in group 1 and 200 in group 2). It will be an
open-label, randomized, multi-centre study in which group 1 will receive Td5ap as a single
injection and group 2 will receive Td1aP as a single injection. DTP antibodies will be
measured before and 28 days (+ 14 days) after Td5ap and Td1aP vaccination. The proportion of
children with positive IgG antibody response will be measured in each study arm. Sera will be
tested blindly by established ELISA methods and saliva samples will be analyzed by
exploratory assays. In a subpopulation cellmediated immunity will be analyzed. The safety
evaluation criteria will be the percentage of subjects with adverse events describing
injection-site adverse reactions, systemic adverse events, daily temperatures and serious
adverse events.
Study Phase
Phase 4
Study Type
Interventional
Primary Outcome
to describe in each arm the immune response to diptheria toxin, tetanus toxoid, pertussis toxin, FHA, fimbriae 2/3 and pertactin four weeks after immunization with Td1aP and Td5ap
Secondary Outcome
safety of a fith dose of DTP vaccines
Condition
Tetanus
Intervention
Td5ap
Study Arms / Comparison Groups
Td5ap
Description: Group 1 receiving Td5ap as a single intramuscular injection.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Biological
Estimated Enrollment
400
Start Date
April 2009
Completion Date
June 2010
Primary Completion Date
October 2009
Eligibility Criteria
Inclusion Criteria:
- healthy subject
- 14-15 years old
- eligible for their school-leaving booster for DTP
- received a complete primary vaccination with a 5-component acellular pertussis vaccine
(DT5aP-IPV-Hib) at 3, 5 and 12 months of age and vaccinated with a 5-component
acellular pertussis vaccine (Td5aP-IPV or Td5aP + IPV) as a booster at 5½ years of age
- informed consent form signed by the subject and parent(s)/legal representative
- subject understand and comply with the study procedures (i.e. able to read and write
Swedish)
- female must provide an agreement that they are either sexually continent or practice
adequate contraceptive methods (intra-uterine contraceptive device (IUCD), hormonal
contraceptives, condoms or other adequate barrier contraception).
Exclusion Criteria:
- acute febrile illness or axillary temperature ≥38.0°C at the time of vaccination
- receipt of immunoglobulin within the previous 3 months, immunosuppression (e g
evidence of impaired cell mediated immunity, receipt of immunosuppressant drugs within
the previous 3 months or receipt of systemic corticosteroids given daily or on
alternate days at ≥20 mg/day prednisone equivalent during >14 days within the past 30
days)
- receipt of a non-study vaccine in the past 30 days
- evolving encephalopathy not attributable to another identifiable cause within 7 days
of administration of a previous dose of any vaccine
- booster vaccination with tetanus, low dose diphtheria and acellular pertussis vaccine
since the booster vaccination at 5½ years of age
- previous clinical or bacteriological diagnosis of diphtheria, tetanus or pertussis
- hypersensitivity to any component of any of the study vaccines
- current participation in any other clinical trial or participation in any clinical
trial in the previous month
- inability to adhere to the protocol, including plans to move from the area
- severe chronic disease
- family history of congenital or hereditary immunodeficiency
- any sever thrombocytopenia or any other coagulation disorder that would contraindicate
intramuscular injection
- any medical condition, which in the opinion of the investigator, might interfere with
the evaluation of the study objectives.
Gender
All
Ages
14 Years - 15 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Contacts
Leif Gothefors, Prof. em., ,
Location Countries
Sweden
Location Countries
Sweden
Administrative Informations
NCT ID
NCT00870350
Organization ID
2008-008195-13
Study Sponsor
Swedish Institute for Infectious Disease Control
Collaborators
MCM Vaccines B.V.
Study Sponsor
Leif Gothefors, Prof. em., Principal Investigator, Swedish Institute for Infectious Disease Control
Verification Date
March 2009